Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haporine-S is an ophthalmic nanoemulsion formulation of cyclosporine developed by DH Bio Co., Ltd. for the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca). Cyclosporine is a calcineurin inhibitor that acts as an immunosuppressant by inhibiting T-cell activation and decreasing the production of pro-inflammatory cytokines. By reducing inflammation on the ocular surface and in the lacrimal glands, it helps to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. Haporine-S was evaluated in a Phase III clinical trial in South Korea to demonstrate non-inferiority to the reference product, Restasis, and subsequently received regulatory approval in South Korea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Haporine-S (cyclosporine).